Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRuijin Hospital

About this trial

To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between March 2019 and March 2024;

Donor had fasting blood glucose and/or HbA1c records

Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0-2

Survived at least 12 weeks after HSCT

Disqualifiers

Active autoimmune diseases such as SLE, rheumatoid arthritis, etc.

Active cardiovascular disease such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any Grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) Functional Class, or a history of myocardial infarction in the 6 months prior to screening;

Other serious medical conditions that may limit the patient's participation in this trial (e.g., progressive infection, uncontrolled diabetes);

HIV infection, or chronic infection with hepatitis B virus (HBsAg-positive) or hepatitis C virus (anti-HCV-positive) that cannot be controlled by medications;

Trial population

Patients who were diagnosed with hematological disorders and underwent allo-HSCT

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups
Group A: Case Group
Group B: Control Group

Trial outcomes

Primary outcomes

1

Overall Survival (OS)

Patient's overall survival time since hematopoietic stem cell transplantation

Time frame
One year-overall survival since hematopoietic stem cell transplantation

Secondary outcomes

1

Non-relapse Mortality (NRM)

NRM after hematopoietic stem cell transplantation

Time frame
One year since hematopoietic stem cell transplantation
2

Relapse-free Survival (RFS)

RFS after hematopoietic stem cell transplantation

Time frame
One year since hematopoietic stem cell transplantation
3

Event-free Survival (EFS)

EFS after hematopoietic stem cell transplantation

Time frame
One year since hematopoietic stem cell transplantation
4

Graft versus Host Disease (GvHD) incidence

GvHD incidence after hematopoietic stem cell transplantation

Time frame
One year since hematopoietic stem cell transplantation

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: